By performing a genome-wide siRNA screen of both a human lung cancer cell line and a murine mutant EGFR-driven lung ADC, this revealed reduced NF1 mRNA expression in both, and furthermore, whilst the EGFR inhibitor erlotinib failed to fully inhibit RAS-ERK signalling when neurofibromin levels were reduced, treatment of neurofibromin-deficient lung cancers with MEK inhibitor restored sensitivity to erlotinib [71]. The gene discussed is MAP2K7; the disease is lung cancer.